
Healx Doses First Patient in Phase 2 Trial of HLX-1502 for Neurofibromatosis Type 1
Healx Doses First Patient in Phase 2 Trial of HLX-1502 for Neurofibromatosis Type 1 Healx, a clinical-stage biotech company utilizing AI to advance treatments for rare diseases, has announced that…













